Pipeline

Vanda Pharmaceuticals will announce its Q4 and full-year 2025 financial results on February 11, 2026. A conference call at 4:30 PM ET will follow, where management will discuss performance, pipeline progress, and corporate developments. Webcast and replay details are available on Vanda’s website. Investors will be assessing the company’s strategy, product performance, and R&D advancements.

Ascendis Pharma unveiled an ambitious 2026 roadmap, projecting significant revenue growth driven by YORVIPATH and SKYTROFA. The company anticipates around €720 million in revenue for 2025 and aims for €500 million in operating cash flow by 2026. Key pipeline advancements include potential approval for TransCon CNP and promising combination therapies. Strategic collaborations and a $120 million share repurchase program underscore Ascendis’ transition to a global biopharma leader.